These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24581673)

  • 21. Hypoxia-inducible factor prolyl-4-hydroxylation in FOXD1 lineage cells is essential for normal kidney development.
    Kobayashi H; Liu J; Urrutia AA; Burmakin M; Ishii K; Rajan M; Davidoff O; Saifudeen Z; Haase VH
    Kidney Int; 2017 Dec; 92(6):1370-1383. PubMed ID: 28847650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.
    Stoumpos S; Crowe K; Sarafidis P; Barratt J; Bolignano D; Del Vecchio L; Małyszko J; Więcek A; Ortiz A; Cozzolino M
    Nephrol Dial Transplant; 2024 Sep; 39(10):1710-1730. PubMed ID: 38573822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials.
    Higashijima Y; Tanaka T; Nangaku M
    Expert Opin Drug Discov; 2013 Aug; 8(8):965-76. PubMed ID: 23642028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease.
    Nissenson AR
    Am J Kidney Dis; 2001 Dec; 38(6):1390-7. PubMed ID: 11728981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.
    Garrido P; Ribeiro S; Fernandes J; Vala H; Rocha-Pereira P; Bronze-da-Rocha E; Belo L; Costa E; Santos-Silva A; Reis F
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K; Tanaka T; Nangaku M
    Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    Wyatt CM; Drüeke TB
    Kidney Int; 2016 Nov; 90(5):923-925. PubMed ID: 27742192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical application and future perspectives of HIF-PH inhibitors].
    Nangaku M
    Nihon Yakurigaku Zasshi; 2024; 159(3):157-159. PubMed ID: 38692879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
    Haase VH
    Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single dose of EGLN1 siRNA yields increased erythropoiesis in nonhuman primates.
    Abrams MT; Koser M; Burchard J; Strapps W; Mehmet H; Gindy M; Zaller D; Sepp-Lorenzino L; Stickens D
    Nucleic Acid Ther; 2014 Dec; 24(6):405-12. PubMed ID: 25272050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
    Kile M; Sudchada P
    Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anemia management in chronic kidney disease and dialysis: a narrative review.
    Collister D; Rigatto C; Tangri N
    Curr Opin Nephrol Hypertens; 2017 May; 26(3):214-218. PubMed ID: 28306566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
    Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of iron in optimizing responses of anemic cancer patients to erythropoietin.
    Glaspy J; Cavill I
    Oncology (Williston Park); 1999 Apr; 13(4):461-73; discussion 477-8, 483-8. PubMed ID: 10234700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
    Kato S; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON.
    Wish JB
    Am J Nephrol; 2022; 53(5):366-371. PubMed ID: 35462360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.